Jessica E (Ravikoff) Allegretti MD
Associate Director, Crohn’s and Colitis Center
Join to View Full Profile
75 Francis St# BrighamBoston, MA 02115
Phone+1 617-732-6389
Dr. Allegretti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jessica Allegretti is a gastroenterologist in Boston, MA and is affiliated with Brigham and Women's Hospital. She received her medical degree from University of Miami Leonard M. Miller School of Medicine and has been in practice 8 years. She is experienced in inflammatory bowel disease.
Education & Training
Mass General Brigham/Brigham and Women's HospitalFellowship, Gastroenterology, 2012 - 2015
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2009 - 2012
University of Miami Leonard M. Miller School of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2011 - 2026
NH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
CT State Medical License 2022 - 2024
American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- Diagnostic Uncertainties and Delayed Treatment Protocols Impact Efficacy of FMT for C. Difficile Infection.Jessica R Allegretti, Monika Fischer, Colleen R Kelly
Clinical Infectious Diseases. 2025-04-22 - Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis.Rahul S Dalal, Lindsay M Clarke, Alex Carlin, Heidy Cabral, Jessica R Allegretti
Inflammatory Bowel Diseases. 2025-04-10 - Treatment of Clostridioides difficile : The Times They Are Changing.Paul Feuerstadt, Jessica Allegretti, Sahil Khanna
The American Journal of Gastroenterology. 2025-04-07
Press Mentions
‘See C. Diff Diagnosed’ Campaign Aims to Spread Awareness, Defuse Public Health ThreatNovember 26th, 2024- Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023May 8th, 2023
- FMT Tops Standard of Care for First or Second C. Diff InfectionsSeptember 29th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
